Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049343 | 0.96 | CSF1R (0.44) | NAMPTCSF1RPDGFRBMAPK7PDGFRA | |
| SCHEMBL12049377 | 0.89 | CSF1R (0.41) | NAMPTCSF1RPDGFRBMAPK7PDGFRA | |
| SCHEMBL12049416 | 0.88 | CSF1R (0.45) | NAMPTCSF1RPDGFRBMAPK7PDGFRA | |
| SCHEMBL12049345 | 0.88 | CSF1R (0.42) | CSF1RPDGFRBMAPK7PDGFRA | |
| SCHEMBL12049274 | 0.86 | ERBB2 (0.45) | NAMPTCSF1RPDGFRBMAPK7 | |
| SCHEMBL12049422 | 0.86 | EGFR (0.47) | NAMPTCSF1RPDGFRBMAPK7 | |
| SCHEMBL12049331 | 0.86 | KDR (0.47) | CSF1RPDGFRBMAPK7PDGFRA | |
| SCHEMBL12049420 | 0.86 | EGFR (0.47) | NAMPTCSF1RPDGFRBMAPK7 | |
| SCHEMBL12049335 | 0.85 | NAMPT (0.47) | NAMPTCSF1RPDGFRBPDGFRA | |
| SCHEMBL12049378 | 0.84 | CSF1R (0.51) | CSF1RPDGFRBMAPK7PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | NAMPT 1570/4885CSF1R 6/4885PDGFRB 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.